The impact of basal insulin analogues on glucose variability in patients with type 2 diabetes undergoing renal replacement therapy for end-stage renal disease
作者： Octavian Savu , Viviana Elian , Oana Steriade , Ileana Teodoru , Stela Mihut
DOI: 10.1007/S11255-015-1175-X
关键词:
摘要: We aimed to analyze the impact of basal insulin analogues on glucose variability (GV) in patients with type 2 diabetes (DM) undergoing renal replacement therapy. Fourteen subjects therapy for at least 6 months (detemir, n = 7 vs. glargine, n = 7) were sequentially enrolled this prospective study. Continuous monitoring system (CGMS Gold, Dex Com 7+) was applied 5 days, over 3 consecutive sessions hemodialysis (HD). Various glycemic profiles (coefficient variation—CV mean glucose) compared between day (HD-on) and off (HD-off) dialysis. The CV values HbA1c (HPLC) since has been assay long-term GV. Endogenous resistance (HOMA using fasting C-peptide levels), lipid profile, quantitative C-reactive protein (CRP) ferritin (values adjusted Hb) measured serum inclusion. overnight HD-off HD-on short-term (CV CGMS) GV, overall HbA1c) CRP reduced treated detemir (paired t test, p = 0.0001, 0.0011, 0.036, 3). Insulin-resistant end-stage disease exhibit lower pro-inflammatory profile than glargine.
springer.com
sci-hub.se 参考文章(27)
Georg Biesenbach, Robert Pichler, Gerd Bodlaj, Jörg Berg, Prevalence, severity and predictors of HOMA-estimated insulin resistance in diabetic and nondiabetic patients with end-stage renal disease. Journal of Nephrology. ,vol. 19, pp. 607- 612 ,(2006)
Leonardo Cacciagiú, Ana I. González, Alicia Elbert, Guillermo De'Marziani, Tetsuo Machida, Masami Murakami, Graciela I. López, Regina Wikinski, Katsuyuki Nakajima, Laura Schreier, Do insulin resistance conditions further impair the lipid and inflammatory profile in end-stage renal disease patients on hemodialysis? Metabolic Syndrome and Related Disorders. ,vol. 12, pp. 220- 226 ,(2014) , 10.1089/MET.2013.0124
M. H. Tan, Effect of Diabetes Mellitus and End-Stage Renal Disease on HDL Metabolism Advances in Experimental Medicine and Biology. ,vol. 201, pp. 51- 59 ,(1986) , 10.1007/978-1-4684-1262-8_5
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine. ,vol. 358, pp. 2560- 2572 ,(2008) , 10.1056/NEJMOA0802987
I A Macdonald, M R Holland, D Forster, R Lodwick, M A Jackson, J Nicholas, Hemodialysis-induced hypoglycemia in diabetic patients. Clinical Nephrology. ,vol. 54, pp. 30- 34 ,(2000)
Sanne G Swinnen, Airin CR Simon, Frits Holleman, Joost B Hoekstra, J Hans DeVries, Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. ,vol. 2011, ,(2011) , 10.1002/14651858.CD006383.PUB2
Vincent Rigalleau, Henri Gin, Carbohydrate metabolism in uraemia. Current Opinion in Clinical Nutrition and Metabolic Care. ,vol. 8, pp. 463- 469 ,(2005) , 10.1097/01.MCO.0000172590.32564.B9
A. Tone, I. Iseda, C. Higuchi, K. Tsukamoto, A. Katayama, Y. Matsushita, K. Hida, J. Wada, K. Shikata, Comparison of insulin detemir and insulin glargine on glycemic variability in patients with type 1 and type 2 diabetes. Experimental and Clinical Endocrinology & Diabetes. ,vol. 118, pp. 320- 324 ,(2010) , 10.1055/S-0029-1243230
Yosef S. Haviv, Mohamad Sharkia, Rifaat Safadi, HYPOGLYCEMIA IN PATIENTS WITH RENAL FAILURE Renal Failure. ,vol. 22, pp. 219- 223 ,(2000) , 10.1081/JDI-100100866
Achilleas N. Pitsillides, Stacey M. Anderson, Boris Kovatchev, Hypoglycemia Risk and Glucose Variability Indices Derived from Routine Self-Monitoring of Blood Glucose Are Related to Laboratory Measures of Insulin Sensitivity and Epinephrine Counterregulation Diabetes Technology & Therapeutics. ,vol. 13, pp. 11- 17 ,(2011) , 10.1089/DIA.2010.0103